Table 1 Patient demographics and clinical characteristics
Category | Insomnia Treated Patients | Matched Control Cohort | ||
|---|---|---|---|---|
Post-Matching | ||||
N | % | N | % | |
Total | 1,699,913 | 100.0% | 1,699,913 | 100.0% |
Sex | ||||
  Female | 1,017,413 | 59.9% | 1,017,413 | 59.9% |
Age at Index | ||||
 Mean (SD) | 75.4 (6.8) | 75.4 (6.8) | ||
 Median (IQR) | 74.0 (70.0—80.0) | 74.0 (70.0—80.0) | ||
 Min (Max) | 65 (111) | 65 (111) | ||
Duration of Post-Index Enrollment (months) | ||||
 Mean (SD) | 40.6 (17.3) | 44.1 (17.0) | ||
 Median (IQR) | 40.2 (25.1—57.2) | 46. (29.4—59.1) | ||
 Min (Max) | 1 (72) | 0 (72) | ||
Charlson Comorbidity Index | ||||
 Mean (SD) | 1.7 (2.5) | 0.7 (1.5) | ||
 Median (IQR) | 1 (0 – 3) | 0 (0 – 1) | ||
 Min (Max) | 0 (24) | 0 (20) | ||
Comorbidities | ||||
 Depression | 296,097 | 17.4% | 56,258 | 3.3% |
 Osteoporosis | 280,462 | 16.5% | 178,721 | 10.5% |
 Traumatic brain injury | 62,318 | 3.7% | 16,672 | 1.0% |
 Alzheimer’s disease and related dementia | 144,834 | 8.5% | 31,812 | 1.9% |
 Chronic pain | 108,468 | 6.4% | 19,222 | 1.1% |
 Obstructive sleep apnea | 113,161 | 6.7% | 0 | 0.0% |
Index Treatment | ||||
 Benzodiazepines | 494,655 | 29.1% |  |  |
 Trazodone | 581,117 | 34.2% |  |  |
 Zolpidem ER | 8,196 | 0.5% |  |  |
 Zolpidem IR | 615,945 | 36.2% |  |  |